Clinical effect of Qishen Yiqi dropping pill on the prognosis of patients with depression after percutaneous coronary intervention

doi:10.11958/20220656

Abstract

Abstract:

Objective To observe the effect of Qishen Yiqi dropping pill on prognosis of patients with coronary heart disease complicated with depression after percutaneous coronary intervention (PCI). Methods A total of 100 patients with coronary heart disease complicated with depression who underwent PCI were divided into the control group and the treatment group by random number table method, with 50 cases in each group. Patients of the control group were treated with conventional Western medicine and psychological counseling after PCI. The treatment group was additionally treated with Qishen Yiqi dropping pill, 0.5 g each time, 3 times a day. Both groups were treated for 4 weeks. The cardiac function related indicators were observed in patients of the two groups. The efficacy of the traditional Chinese medicine (TCM) syndrome and depression mood improvement were also observed. Results Before treatment, there were no significant differences in left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) between the two groups. After treatment, LVEF was higher in both groups than that before treatment, while LVEDD was lower (P<0.05). LVEF was significantly higher in the treatment group than that in the control group, while LVEDD was lower (P<0.05). In terms of curative effect of TCM syndromes, the total effective rate was higher in the treatment group than that of the control group (92.0% vs. 76.0%, χ²=4.762, P<0.05). Before treatment, there was no significant difference in HAMD-17 score between the two groups. After treatment, HAMD-17 score was lower than that before treatment in both groups (P<0.05), and HAMD-17 score was significantly lower in the treatment group than that in the control group (P<0.05). The effective rate of depression was significantly higher in the treatment group than that in the control group (90.0% vs. 74.0%, χ²=4.336, P<0.05). Conclusion Qishen Yiqi dropping pill can not only improve the myocardial blood supply, but also effectively improve the psychological state of patients and relieve the depression.

Key words: coronary disease, depression, percutaneous coronary intervention, Qishen Yiqi dropping pill

CLC Number:

R541.4

Figures/Tables 4

References 24

[1]	葛均波. 动脉粥样硬化和冠状动脉粥样硬化性心脏病[M]. //陈灏珠,钟南山,陆再英. 内科学. 8版. 北京: 人民卫生出版社, 2013:220-256.
	GE J B. Atherosclerosis and coronary atherosclerotic heart disease[M]. //CHEN H Z,ZHONG N S,LU Z Y. Internal Medicine. 8th ed. Beijing: People's Medical Publishing House, 2013:220-256.
[2]	陈宗宁, 赵渊, 庄莉. PCI治疗重症冠心病的安全性和远期疗效[J]. 中国循证心血管医学杂志, 2017, 9(12):1452-1454.
	CHEN Z N, ZHAO Y, ZHUANG L. Safety and long-term curative effect of percutaneous coronary intervention in treatment of severe coronary artery disease[J]. Chin J Evid Based Cardiovasc Med, 2017, 9(12):1452-1454. doi:10.3969/j.issn.1674-4055.2017.12.11.
[3]	姬林娟, 李星辉, 孙小龙, 等. 甘肃农村地区冠心病患者经皮冠状动脉介入治疗术后抑郁及焦虑状况调查[J]. 中国介入心脏病学杂志, 2020, 28(12):700-704.
	JI L J, LI X H, SUN X L, et al. A survey of depression and anxiety after percutaneous coronary intervention in rural areas of Gansuprovince[J]. Chinese Journal of Interventional Cardiology, 2020, 28(12):700-704. doi:10.3969/j.issn.1004-8812.2020.12.008.
[4]	袁炜, 梁潇, 刘盈盈, 等. 冠心病患者PCI后合并抑郁状态的调查研究[J]. 中国循证心血管医学杂志, 2021, 13(9):1046-1049,1053.
	YUAN W, LIANG X, LIU Y Y, et al. A survey on depression in patient with coronary heart disease after percutaneous coronary intervention[J]. Chin J Evid Based Cardiovasc Med, 2021, 13(9):1046-1049,1053. doi:10.3969/j.issn.1674-4055.2021.09.05.
[5]	刘梅颜, 胡大一, 姜荣环, 等. 心血管内科门诊患者合并心理问题的现状分析[J]. 中华内科杂志, 2008, 47(4):277-280.
	LIU M Y, HU D Y, JIANG R H, et al. An analysis of psychological problems of patients in cardiology clinic[J]. Chinese Journal of Internal Medicine, 2008, 47(4):277-280. doi:10.3321/j.issn.0578-1426.2008.04.006.
[6]	周善洁, 刘培珍, 王凯歌, 等. 甘肃地区心血管疾病住院患者焦虑抑郁状态单中心调查[J]. 中国循证心血管医学杂志, 2021, 13(8):994-998.
	ZHOU S J, LIU P Z, WANG K G, et al. A single-center survey on anxiety and depression in inpatients with cardiovascular disease in Gansu[J]. Chin J Evid Based Cardiovasc Med, 2021, 13(8):994-998. doi:10.3969/j.issn.1674-4055.2021.08.24.
[7]	彭婷, 何平平, 雷琼, 等. 经皮冠状动脉介入治疗术后患者希望水平与焦虑抑郁及应对方式的相关性[J]. 中国当代医药, 2022, 29(10):147-150.
	PENG T, HE P P, LEI Q, et al. Correlation between hope level and anxiety, depression and coping style in patients after percutaneous coronary intervention[J]. China Modern Medicine, 2022, 29(10):147-150. doi:10.3969/j.issn.1674-4721.2022.10.040.
[8]	KHANDAKER G M, ZUBER V, REES J, et al. Correction:Shared mechanisms between coronary heart disease and depression:findings from a large UK general population-based cohort[J]. Mol Psychiatry, 2021, 26(7):3659-3661. doi:10.1038/s41380-020-0857-7.
[9]	王计亮, 薛静. 芪参益气滴丸联合替格瑞洛对急性冠脉综合征PCI术后血小板功能、炎性细胞因子及预后的影响[J]. 现代中西医结合杂志, 2019, 28(19):2134-2137.
	WANG J L, XUE J. Effects of Qishen Yiqi Drop Pill combined with ticagrelor on platelet function,inflammatory cytokines,and prognosis after PCI in acute coronary syndrome[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2019, 28(19):2134-2137. doi:10.3969/j.issn.1008-8849.2019.19.020.
[10]	曹波. 我院20岁及以上居民冠心病发病率变化趋势及类型分析[J]. 心血管病防治知识, 2017, 7(4):32-34.
	CAO B. Change trend of the incidence of coronary heart disease in residents aged 20 years or above in our hospital and related disease types[J]. Prevention and Treatment of Cardiovascular Disease, 2017, 7(4):32-34. doi:10.3969/j.issn.1672-3015.2017.04.014.
[11]	CARNEY R M, FREEDLAND K E, STEINMEYER B C, et al. Residual symptoms after treatment for depression in patients with coronary heart disease[J]. Psychosom Med, 2018, 80(4):385-392. doi:10.1097/PSY.0000000000000570.
[12]	夏啸. 急性心肌梗死患者PCI术后心理障碍影响因素及与自主神经功能关系研究[D]. 武汉: 湖北中医药大学, 2020.
	XIA X. Effect factors of psychological disorders and their relationship with autonomic function after PCI in patients with acute myocardial infarction[D]. Wuhan: Hubei University of Traditional Chinese Medicine, 2020.
[13]	孙毅, 张权宇, 刘威, 等. 经皮冠状动脉介入治疗术后冠心病患者合并焦虑和(或)抑郁对预后影响[J]. 临床军医杂志, 2020, 48(5):518-520,525.
	SUN Y, ZHANG Q Y, LIU W, et al. Effects of anxiety and/or depression on the clinical prognosis of patients with coronary artery disease after percutaneous cor-onary intervention[J]. Clinical Journal of Medical Officers, 2020, 48(5):518-520,525. doi:10.16680/j.1671-3826.2020.05.11.
[14]	DAMEN N L, VERSTEEG H, BOERSMA E, et al. Depression is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention:results from the RESEARCH registry[J]. Int J Cardiol, 2013, 167(6):2496-2501. doi:10.1016/j.ijcard.2012.04.028.
[15]	杨炼, 许滔. 基于《内经》理论初探双心医学的疾病发病及防治机制[J]. 贵阳中医学院学报, 2017, 39(5):5-8,15.
	YANG L, XU T. Based on the theory of internal jing,the disease pathogenesis and prevention mechanism of double heart medicine[J]. Journal of Guiyang College of Traditional Chinese Medicine, 2017, 39(5):5-8,15. doi:10.16588/j.cnki.issn1002-1108.2017.05.002.
[16]	汪东东. 加味大柴胡汤治疗冠心病稳定型心绞痛合并抑郁症的临床研究[D]. 郑州: 河南中医药大学, 2018:24-25.
	WANG D D. Clinical study in treating stable angina pectoris with depression[D]. Zhengzhou: Henan University of Traditional Chinese Medicine, 2018:24-25.
[17]	刘薇, 张玉焕, 李争. 芪参益气滴丸对老年气虚血瘀型心力衰竭患者心肌保护、炎症状态的影响[J]. 陕西中医, 2021, 42(1):37-40.
	LIU W, ZHANG Y H, LI Z. Effects of Qishen Yiqi dropping pills on myocardial protection,inflammatory state and serum cell adhesion molecule level in elderly patients with heart failure caused by qi deficiency and blood stasis[J]. Shaanxi Journal of Traditional Chinese Medicine, 2021, 42(1):37-40. doi:10.3969/j.issn.1000-7369.2021.01.008.
[18]	TU L, PAN C S, WEI X H, et al. Astragaloside IV protects heart from ischemia and reperfusion injury via energy regulation mechanisms[J]. Microcirculation, 2013, 20(8):736-747. doi:10.1111/micc.12074.
[19]	范竹鸣, 王佑华, 谢瑞芳, 等. 降香化学成分和药理作用研究进展[J]. 时珍国医国药, 2016, 27(10):2478-2480.
	FAN Z M, WANG Y H, XIE R F, et al. Progress in the chemical composition and pharmacological effects of incense reduction[J]. Lishizhen Medicine and Materia Medica Research, 2016, 27(10):2478-2480. doi:10.3969/j.issn.1008-0805.2016.10.063.
[20]	王昆, 戴小华. 芪参益气滴丸改善急性心肌梗死后左室重构、心功能疗效及安全性的Meta分析[J]. 中西医结合心脑血管病杂志, 2019, 17(5):653-658.
	WANG K, DAI X H. Efficacy and safety of Qishen Yiqi dripping pill in improving left ventricular remodeling and cardiac function after acute myocardial infarction:a Meta-analysis[J]. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascuiar Disease, 2019, 17(5):653-658. doi:10.12102/j.issn.1672-1349.2019.05.003.
[21]	张华林, 李梦涛, 彭灏, 等. 三七叶总皂苷酶解产物的制备及抗抑郁活性评价[J]. 中国实验方剂学杂志, 2014, 20(3):1-5.
	ZHANG H L, LI M T, PENG H, et al. Preparation of enzymatic hydrolysates from Total Saponins in leaves of Notoginseng Radix Et Rhizoma and evaluation of its antidepressant effects[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2014, 20(3):1-5. doi:10.11653/syfj2014030001.
[22]	陈俊玲, 傅如华. 活血化瘀解郁方治疗气滞血瘀型脑卒中后抑郁的疗效分析[J]. 中西医结合心血管病电子杂志, 2019, 7(29):149.
	CHEN J L, FU R H. Analysis of the efficacy of activating blood stasis in treating depression after qi stagnation and blood stasis[J]. Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine(Electronic), 2019, 7(29):149.
[23]	张立娟, 张进强, 贺慧, 等. 丹参抗抑郁的神经免疫机制研究探讨[J]. 世界科学技术-中医药现代化, 2017, 19(8):1289-1293.
	ZHANG L J, ZHANG J Q, HE H, et al. Antidepressant effects of salvia through neuroinflammatory signaling related to neurogenesis[J]. World Science and Technology-Modernization of Traditional Chinese Medicine, 2017, 19(8):1289-1293. doi:10.11842/wst.2017.08.005.
[24]	宋巍巍, 刁邵敏. 芪参益气滴丸联合常规西药治疗心脏神经症的临床观察[J]. 中国民间疗法, 2020, 28(4):45-47.
	SONG W W, DIAO S M. Clinical observation of Qishen Yiqi Dipill combined with conventional western medicine in the treatment of cardiac neurosis[J]. China's Naturopathy, 2020, 28(4):45-47. doi:10.19621/j.cnki.11-3555/r.2020.0420.

组别	n	性别（男/女）	年龄（岁）	病程（年）	BMI （kg/m²）	抑郁程度			既往病史
组别	n	性别（男/女）	年龄（岁）	病程（年）	BMI （kg/m²）	轻度	中度	重度	糖尿病	高血压	高脂血症	脑卒中
对照组	50	28/22	58.3±6.9	3.8±1.2	24.8±1.7	13（26.0）	26（52.0）	11（22.0）	9（18.0）	11（22.0）	15（50.0）	4（8.0）
治疗组	50	29/21	58.9±7.1	3.9±1.3	25.0±1.9	15（30.0）	25（50.0）	10（20.0）	8（16.0）	10（20.0）	16（32.0）	2（4.0）
χ²或t		0.041	0.447	0.399	0.555	0.210			0.071	0.060	0.047	0.709

组别	n	性别（男/女）	年龄（岁）	病程（年）	BMI （kg/m²）	抑郁程度			既往病史
组别	n	性别（男/女）	年龄（岁）	病程（年）	BMI （kg/m²）	轻度	中度	重度	糖尿病	高血压	高脂血症	脑卒中
对照组	50	28/22	58.3±6.9	3.8±1.2	24.8±1.7	13（26.0）	26（52.0）	11（22.0）	9（18.0）	11（22.0）	15（50.0）	4（8.0）
治疗组	50	29/21	58.9±7.1	3.9±1.3	25.0±1.9	15（30.0）	25（50.0）	10（20.0）	8（16.0）	10（20.0）	16（32.0）	2（4.0）
χ²或t		0.041	0.447	0.399	0.555	0.210			0.071	0.060	0.047	0.709

组别	n		LVEF
组别	n		治疗前		治疗后		t
对照组	50		0.438±0.039		0.468±0.047		3.400^＊
治疗组	50		0.436±0.037		0.509±0.050		8.328^＊
t			0.315		4.283^＊
组别		LVEDD（mm）
组别		治疗前		治疗后		t
对照组		54.63±3.97		51.05±3.56		4.747^＊
治疗组		54.92±3.91		47.14±3.37		10.657^＊
t		0.368		5.640^＊

组别	n		LVEF
组别	n		治疗前		治疗后		t
对照组	50		0.438±0.039		0.468±0.047		3.400^＊
治疗组	50		0.436±0.037		0.509±0.050		8.328^＊
t			0.315		4.283^＊
组别		LVEDD（mm）
组别		治疗前		治疗后		t
对照组		54.63±3.97		51.05±3.56		4.747^＊
治疗组		54.92±3.91		47.14±3.37		10.657^＊
t		0.368		5.640^＊

组别	n	治疗前	治疗后	t
对照组	50	25.91±3.74	22.63±3.25	4.753^＊
治疗组	50	25.65±3.58	17.56±2.92	14.681^＊
t		0.355	8.205^＊